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Peripheral blood monocytes are responsible for cd T cell
activation induced by zoledronic acid through accumulation
of IPP/DMAPP
Nitrogen-containing bisphosphonate drugs (N-BPs) are effec-
tive anti-resorptive agents commonly used for the treatment
of postmenopausal osteoporosis and tumour-induced osteo-
lysis. Intravenous administration of N-BPs is commonly
associated with a ﬂu-like acute-phase reaction involving the
activation of Vc9Vd2 T cells (Kunzmann et al, 2000). As
Vc9Vd2 T cells have potent anti-tumoural properties, acti-
vation and expansion of Vc9Vd2 T cells by N-BPs offers a
promising strategy for cancer immunotherapy (Bonneville &
Scotet, 2006). N-BPs, like dietary alkylamines, activate
Vc9Vd2 T cells through inhibition of farnesyl diphosphate
(FPP) synthase (Gober et al, 2003; Thompson & Rogers,
2004; Hewitt et al, 2005; Thompson et al, 2006a), most likely
via an accumulation of the substrates of FPP synthase,
isopentenyl diphosphate (IPP) and its stereoisomer dimeth-
ylallyl diphosphate (DMAPP), which are agonists of the
Vc9Vd2 T cell receptor (TCR) (Tanaka et al, 1995). However,
the exact cell type in peripheral blood that accumulates IPP/
DMAPP after exposure to N-BP remains unknown. Mono-
cytes have previously been shown to be required for
activation of Vc9Vd2 T cells by the N-BP pamidronate
(Miyagawa et al, 2001), although the role of monocytes was
thought to be direct presentation of N-BP to the Vc9Vd2
TCR (Miyagawa et al, 2001). It has since become clear that
the activation of Vc9Vd2 T cells by N-BPs involves intracel-
lular N-BP uptake and IPP/DMAPP accumulation (Gober
et al, 2003; Thompson & Rogers, 2004). We hypothesized
that monocytes, due to their high endocytic activity, are the
peripheral blood cells that efﬁciently internalize N-BP and
accumulate IPP/DMAPP, and therefore are directly respon-
sible for triggering Vc9Vd2 T cell activation.
Materials and methods
Reagents
Zoledronic acid (ZOL) and CGP-58318 (an analogue of ZOL;
Legay et al, 2002) were provided by Novartis Pharma AG
(Basel, Switzerland). All other reagents were from Sigma
Chemical Company (Poole, Dorset, UK), unless otherwise
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Summary
Nitrogen-containing bisphosphonates indirectly activate Vc9Vd2 T cells
through inhibition of farnesyl pyrophosphate synthase and intracellular
accumulation of isopentenyl diphosphate (IPP) and dimethylallyl
diphosphate (DMAPP), but the cells responsible for Vc9Vd2 T cell
activation through IPP/DMAPP accumulation are unknown. Treatment of
human peripheral blood mononuclear cells (PBMCs) with a
pharmacologically relevant concentration of zoledronic acid induced
accumulation of IPP/DMAPP selectively in monocytes, which correlated
with efﬁcient drug uptake by these cells. Furthermore, zoledronic acid-pulsed
monocytes triggered activation of cd T cells in a cell contact-dependent
manner. These observations identify monocytes as the cell type directly
affected by bisphosphonates responsible for Vc9Vd2 T cell activation.
Keywords: bisphosphonates, alkylamines, monocytes, gamma delta T cells,
isopentenyl diphosphate.
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form by dissolving 5 mg in 100 ll of ethanol and 100 ll1N
NaOH, adding 1 ml phosphate buffered saline (PBS), and
adjusting the pH to 8 using 1 N HCl. CGP-58318 was
conjugated through the primary amine group to Alexa Fluor
488 (AF488-BP) or Alexa Fluor 680 (AF680-BP) as previously
described for alendronate (Thompson et al, 2006b).
Cell culture and treatment
This study was approved by the North of Scotland Research
Ethics Committee. Informed consent was obtained for the
collection of peripheral blood from healthy volunteers in
accordance with the Declaration of Helsinki. Peripheral blood
mononuclear cells (PBMCs) were isolated using Lymphoprep
(Axis-Shield, Oslo, Norway) density gradient centrifugation
and cultured in a-minimal essential medium supplemented
with 100 U/ml penicillin, 100 lg/ml streptomycin, 2 mmol/l
glutamine, 10% fetal bovine serum, and 10 U/ml recombinant
human interleukin 2, except for detection of drug uptake
where PBMCs were isolated using PharmLyse (BD Biosciences,
Oxford, UK). Murine J774Æ2 macrophage-like cells were
cultured as previously described (Thompson et al, 2006b),
and plated at 5 · 10
5 cells/well in 6-well plates and allowed to
adhere overnight. The cells were then treated as indicated in
the ﬁgure legends for 24 h before harvesting.
Detection and quantiﬁcation of IPP/DMAPP and ApppI
Human PBMCs (2 · 10
6 cells/ml in 75 cm
2 ﬂasks) or J774Æ2
macrophages (5 · 10
5 cells/well in 6-well plates) were treated
as indicated in the ﬁgure legends, and T cells or monocytes
were puriﬁed from human PBMCs by negative selection using
MACS beads (Miltenyi Biotech GmbH, Bergisch Gladbach,
Germany) according to manufacturer’s instructions. IPP/
DMAPP and ApppI were quantiﬁed by high performance
liquid chromatography negative ion electrospray ionization
mass spectrometry (HPLC-ESI-MS) in acetonitrile extracts, as
previously described (Mo ¨nkko ¨nen et al, 2006), and results
were expressed per milligram protein, determined by Bradford
assay.
Detection of drug uptake
Human PBMCs (1 · 10
6 cells/well in 24-well plates) were
treated as indicated in the legend of Fig 1, washed twice in ice-
cold PBS, and stained with anti-CD14 (Miltenyi Biotech) or
anti-CD3 antibodies (Beckman Coulter Immunotech, Palo
Alto, CA, USA). Formaldehyde-ﬁxed cells were analysed on an
LSRII(BDBiosciences)ﬂowcytometerusingfacsdivasoftware
(BD Biosciences), or cytospun onto slides and counterstained
with SYTOX Orange (Invitrogen, Paisley, UK) prior to analysis
on a Zeiss LSM510 META system (Carl Zeiss Ltd, Welwyn
Garden City, UK) using a 63· objective lens, and aim software
(Carl Zeiss Ltd) for image acquisition and analysis.
Co-culture of ZOL-treated monocytes with cd T cells
Monocytes were isolated from human PBMCs using anti-CD14
magnetic bead separation (Miltenyi Biotec GmbH) according to
the manufacturer’s instructions. Purity of the monocyte fraction
was ‡93%, as assessed by CD14-labelling and ﬂow cytometric
analysis.Isolatedmonocyteswereplatedoutat5 · 10
5 cells/well
in 24-well plates, pulse-treated with 1 lmol/l ZOL or vehicle for
2 h, then washed with PBS. Vehicle- or ZOL-treated monocytes
(1 · 10
5 cells/well) were then co-cultured with the monocyte-
depleted PBMCs (5 · 10
5 cells/well) or with cd T cells
(1 · 10
4 cells/well) isolated from the monocyte-depleted frac-
tion using a negative cd T cell isolation kit (Miltenyi Biotec
GmbH),inaﬁnalvolumeof500 llmediumin24-wellplates.To
assess the role of cell–cell contact, transwell inserts (pore-size
0Æ4 lm) were used to separate monocyte-depleted PBMCs or cd
T cells from monocytes.
Detection of interferon-c release
After 72 h, conditioned medium was collected and the
concentration of interferon (IFN)-c was determined using an
IFN-c Quantikine enzyme-linked immunosorbent assay kit
(R&D Systems, Minneapolis, MN, USA) according to the
manufacturer’s instructions.
Detection of cd T cell proliferation
After 7 d, the percentage of Vd2-TCR
+ T cells in the PBMC
co-cultures was determined by immunostaining with anti-CD3
and anti-Vd2-TCR antibodies and ﬂow cytometric analysis, as
previously described (Thompson et al, 2006a).
Results and discussion
ZOL and sec-butylamine induce IPP/DMAPP
accumulation in J774Æ2 macrophages and this is prevented
by mevastatin
Recent studies have suggested that accumulation of IPP/
DMAPP triggers Vc9Vd2 T cell activation by N-BPs as well as
alkylamines (Gober et al, 2003; Thompson & Rogers, 2004;
Hewitt et al, 2005; Thompson et al, 2006a). However, the IPP/
DMAPP accumulation in response to pharmacological inhibi-
tion of FPP synthase is not well characterized. We used
quantitative HPLC-ESI-MS to assess intracellular IPP/DMAPP
levelsinresponsetoZOLtreatmentinJ774Æ2macrophages.Low
concentrations of ZOL (‡0Æ5 lmol/l) were sufﬁcient to cause
detectable accumulation of IPP/DMAPP (Fig S1A). In addition,
thealkylaminesec-butylamine (SBA)alsoinducedIPP/DMAPP
accumulation at concentrations ‡5 mmol/l (Fig S1A). The
relatively high concentration of SBA required to induce IPP/
DMAPP accumulation correlated with the far lower potency of
alkylamines for inhibiting FPP synthase than ZOL (Thompson
et al, 2006a). Simultaneous treatment with MEV almost com-
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Fig 1. ZOL induces IPP/DMAPP accumulation selectively in monocytes and this is associated with high levels of intracellular drug uptake. (A) Human
PBMCswerepulse-treatedwith1 lmol/lZOLfor2 h,washedandfurtherculturedfor22 hindrug-freemedium.Cellswerepuriﬁedintomonocyteand
non-monocyte fractions using magnetic bead separation and IPP/DMAPP was detected in acetonitrile cell extracts by HPLC-ESI-MS. Data shown are
representative of two experiments from independent donors. Chromatograms were drawn on the same scale. No IPP/DMAPP was detected in extracts
from untreated cells. (B–D) Human PBMCs were treated with 20 lmol/l AF680-BP for 24 h, washed, and stained with either anti-CD3-ﬂuorescein
isothiocyanate(FITC)oranti-CD14-FITC.FixedcellswerethenanalysedonanLSRIIﬂowcytometer.Representativeﬂuorescencescatterplotsareshown
of control cells and cells treated with AF680-BP, labelled with anti-CD14-FITC (B) or anti-CD3-FITC (C). CD3-stained cells were gated for the
lymphocyte population based on forward versus side scatter proﬁle. (D) Quantiﬁcation of results shown in panels B and C using facsdiva software.
Resultsarecorrectedforbackgroundﬂuorescence,anddataareexpressedasmean ± standarderrorofthemeanrelativeﬂuorescenceunits(RFU)ofnine
independentdonorsfromﬁveexperiments.(E–F)HumanPBMCsweretreatedwith(E)either50 lmol/lAF488-BP(green)or250 lg/mlFITC-dextran
(green), or (F) 50 lmol/l AF488-BP (green) and 250 lg/ml TRITC-dextran (red), for 24 h. Cells were washed and stained with anti-CD14-allophyc-
ocyanin antibody (blue). Cell nuclei were visualised in (E) by counter-staining with SYTOX Orange (red). Formaldehyde-ﬁxed and cytospun cells were
analysed on a Zeiss LSM510 META system. White bars indicate 10 lm. Images show representative results from at least two independent donors.
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accumulation (Fig S1A). These ﬁndings provide further
evidence for the notion that statins, through inhibiting HMG-
CoA reductase upstream of FPP synthase, prevent
N-BP- and alkylamine-induced Vc9Vd2 T cell activation by
preventingtheaccumulationofIPP/DMAPPresultingfromFPP
synthase inhibition (Gober et al, 2003; Thompson & Rogers,
2004; Hewitt et al, 2005; Thompson et al, 2006a), and further
conﬁrm the mechanism of Vc9Vd2 T cell activation and
proliferation by FPP synthase inhibitors. The accumulation of
IPP/DMAPP in J774Æ2 cells in response to both ZOL and SBA
was associated with a concurrent accumulation of the recently
identiﬁednovelIPPmetaboliteApppI(Mo ¨nkko ¨nenet al,2006),
and this was also blocked by MEV (Fig S1B). Whether the
metabolismofIPPintoApppIaffectstheactivationofVc9Vd2T
cells by N-BPs or alkylamines is presently unknown.
Monocytes accumulate IPP/DMAPP in response
to ZOL in human PBMC cultures
To investigate which cell type in peripheral blood is responsible
for the IPP/DMAPP accumulation and resulting Vc9Vd2 T cell
activationbyN-BPs,weassessedintracellularIPP/DMAPPlevels
in human PBMC cultures in response to ZOL treatment. IPP/
DMAPP could not be detected in untreated cells, but when
human PBMCs were pulsed for 2 h with 10 lmol/l ZOL, IPP/
DMAPP was clearly detectable in the non-T cell fraction,
whereas T cells showed only minor levels of IPP/DMAPP (Fig
S2). The MS/MS spectrum from the peak in the non-T cell
fraction was identical to the MS/MS spectrum of synthetic IPP
(not shown). When human PBMCs were pulsed with 1 lmol/l
ZOL for 2 h (to mimic the estimated circulating concentration
andexposureofperipheralbloodcellsfollowingastandarddose
of ZOL in vivo; Chen et al, 2002), ZOL-induced IPP/DMAPP
accumulation was clearly detectable in monocytes puriﬁed by
magnetic bead separation, but hardly detectable in the non-
monocyte fraction (Fig 1A). Isolation of monocytes based on
cell adherence yielded similar results (not shown).
Peripheral blood monocytes efﬁciently internalize N-BP
We have shown recently that ﬂuid-phase endocytosis is the
major route by which N-BPs are internalized in J774Æ2
macrophages and osteoclasts (Thompson et al, 2006b). Since
peripheral blood monocytes are highly endocytic, we investi-
gated whether the selective accumulation of IPP/DMAPP in
this cell type correlated with relatively high levels of drug
uptake. Indeed, in cultures of PBMCs, only CD14
+ monocytes
internalized large amounts of ﬂuorescently labelled N-BP,
while little or no uptake by other cell types, including CD3
+
lymphocytes, could be detected at the concentrations and
treatment duration used (Fig 1B-D). Similarly, only mono-
cytes internalized large amounts of dextran (Fig 1E), a marker
of ﬂuid-phase endocytosis, and confocal microscopy demon-
strated intracellular co-localization of ﬂuorescently labelled
N-BP with dextran (Fig 1F). This suggests that N-BP uptake by
peripheral blood monocytes, similar to that by J774Æ2 macro-
phages and osteoclasts (Thompson et al, 2006b), predomi-
nantly occurs via ﬂuid-phase endocytosis. Together, these
ﬁndings indicate that, following an intravenous infusion of
ZOL, only highly endocytic monocytes in peripheral blood are
likely to internalize sufﬁcient ZOL to cause a signiﬁcant
accumulation of IPP/DMAPP.
ZOL-pretreated monocytes activate Vc9Vd2 T cells in
human PBMC cultures, and this is dependent
on cell–cell contact
Having shown that monocytes accumulate detectable levels of
IPP/DMAPP following treatment with a clinically relevant
pulse of ZOL (1 lmol/l for 2 h), we investigated whether
puriﬁed peripheral blood monocytes pretreated with the same
concentration and duration of ZOL activated Vc9Vd2 T cells
in co-cultures with untreated (monocyte-depleted) PBMCs.
ZOL-treated monocytes induced a 2Æ5±1 Æ2-fold (n =3 )
increase in IFN-c release when co-cultured with monocyte-
depleted PBMCs, as compared to co-culture of monocyte-
depleted PBMCs with vehicle-treated monocytes (Fig 2A),
although this did not reach statistical signiﬁcance. The increase
in IFN-c correlated with a 2Æ1±0 Æ5-fold (n = 3) increase
(P <0 Æ05) in Vd2
+ T cell number after a 7 d culture (Fig 2B),
and an increase in cell clustering (not shown) in co-cultures
with ZOL-treated monocytes as compared to co-cultures with
vehicle treated-monocytes. Both IFN-c release and Vd2
+ T cell
proliferation were prevented when the monocyte-depleted
PBMCs were separated from monocytes using transwell
inserts, indicating that cell–cell contact is required for the
activation of Vc9Vd2 T cells by ZOL-treated monocytes.
ZOL-pretreated monocytes activate puriﬁed cd T cells
Finally, we investigated whether ZOL-pretreated monocytes
activated Vc9Vd2 T cells in enriched cd T cell cultures. After
72 h, IFN-c release was signiﬁcantly increased in co-cultures
of cd T cells with ZOL-treated monocytes, compared to
co-cultures with vehicle-treated monocytes (P <0 Æ05; Fig 2C).
As observed in the co-cultures of monocytes with monocyte-
depleted PBMCs, the increase in IFN-c release was abrogated
when cd T cells were separated from monocytes using
transwell inserts (Fig 2C). This strongly suggests that ZOL-
treated monocytes can directly activate cd T cells via a cell
contact-dependent mechanism.
Conclusions
This study demonstrated that ZOL induced IPP/DMAPP
accumulation selectively in monocytes following treatment
with a clinically-relevant dose and duration of ZOL, most
probably a result of efﬁcient intracellular drug uptake by this
highly endocytic cell type. Furthermore, peripheral blood
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proliferation of Vc9Vd2 T cells, both in mixed PBMC cultures,
and in co-cultures with enriched cd T cells. These ﬁndings
provide a novel explanation for why monocytes are essential
for Vc9Vd2 T cell activation by N-BPs, and suggest that
monocytes, following exposure to ZOL, can directly activate
Vc9Vd2 T cells in a cell contact-dependent manner.
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